Cargando…

The Clinical Value of Autoantibodies in Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a highly heterogeneous syndrome in terms of clinical presentation, progression, and response to therapy. In such a complicated context, the identification of disease-related biomarkers would be undoubtedly helpful in assisting tailored approaches for every patient. Despi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bugatti, Serena, Manzo, Antonio, Montecucco, Carlomaurizio, Caporali, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287017/
https://www.ncbi.nlm.nih.gov/pubmed/30560132
http://dx.doi.org/10.3389/fmed.2018.00339
_version_ 1783379559848083456
author Bugatti, Serena
Manzo, Antonio
Montecucco, Carlomaurizio
Caporali, Roberto
author_facet Bugatti, Serena
Manzo, Antonio
Montecucco, Carlomaurizio
Caporali, Roberto
author_sort Bugatti, Serena
collection PubMed
description Rheumatoid arthritis (RA) is a highly heterogeneous syndrome in terms of clinical presentation, progression, and response to therapy. In such a complicated context, the identification of disease-related biomarkers would be undoubtedly helpful in assisting tailored approaches for every patient. Despite remarkable efforts, however, progress in new biomarker development and validation is dramatically slow. At present, none of the candidate genetic, cellular, or molecular biomarker has yet surpassed the clinical value of RA-specific autoantibodies, including rheumatoid factor (RF) and anti-citrullinated protein autoantibodies (ACPA). Rather, recent years have witnessed significant advancements in our understanding of the multiple roles that RF and ACPA play in RA pathophysiology. This has helped clarifying the mechanistic basis of the clinical associations of autoantibodies in RA. In this short review, we will briefly summarize the effector functions of RF and ACPA, and analyse how autoantibodies may help subclassifying RA patients in terms of clinical presentation and response to therapy.
format Online
Article
Text
id pubmed-6287017
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62870172018-12-17 The Clinical Value of Autoantibodies in Rheumatoid Arthritis Bugatti, Serena Manzo, Antonio Montecucco, Carlomaurizio Caporali, Roberto Front Med (Lausanne) Medicine Rheumatoid arthritis (RA) is a highly heterogeneous syndrome in terms of clinical presentation, progression, and response to therapy. In such a complicated context, the identification of disease-related biomarkers would be undoubtedly helpful in assisting tailored approaches for every patient. Despite remarkable efforts, however, progress in new biomarker development and validation is dramatically slow. At present, none of the candidate genetic, cellular, or molecular biomarker has yet surpassed the clinical value of RA-specific autoantibodies, including rheumatoid factor (RF) and anti-citrullinated protein autoantibodies (ACPA). Rather, recent years have witnessed significant advancements in our understanding of the multiple roles that RF and ACPA play in RA pathophysiology. This has helped clarifying the mechanistic basis of the clinical associations of autoantibodies in RA. In this short review, we will briefly summarize the effector functions of RF and ACPA, and analyse how autoantibodies may help subclassifying RA patients in terms of clinical presentation and response to therapy. Frontiers Media S.A. 2018-12-03 /pmc/articles/PMC6287017/ /pubmed/30560132 http://dx.doi.org/10.3389/fmed.2018.00339 Text en Copyright © 2018 Bugatti, Manzo, Montecucco and Caporali. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Bugatti, Serena
Manzo, Antonio
Montecucco, Carlomaurizio
Caporali, Roberto
The Clinical Value of Autoantibodies in Rheumatoid Arthritis
title The Clinical Value of Autoantibodies in Rheumatoid Arthritis
title_full The Clinical Value of Autoantibodies in Rheumatoid Arthritis
title_fullStr The Clinical Value of Autoantibodies in Rheumatoid Arthritis
title_full_unstemmed The Clinical Value of Autoantibodies in Rheumatoid Arthritis
title_short The Clinical Value of Autoantibodies in Rheumatoid Arthritis
title_sort clinical value of autoantibodies in rheumatoid arthritis
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287017/
https://www.ncbi.nlm.nih.gov/pubmed/30560132
http://dx.doi.org/10.3389/fmed.2018.00339
work_keys_str_mv AT bugattiserena theclinicalvalueofautoantibodiesinrheumatoidarthritis
AT manzoantonio theclinicalvalueofautoantibodiesinrheumatoidarthritis
AT montecuccocarlomaurizio theclinicalvalueofautoantibodiesinrheumatoidarthritis
AT caporaliroberto theclinicalvalueofautoantibodiesinrheumatoidarthritis
AT bugattiserena clinicalvalueofautoantibodiesinrheumatoidarthritis
AT manzoantonio clinicalvalueofautoantibodiesinrheumatoidarthritis
AT montecuccocarlomaurizio clinicalvalueofautoantibodiesinrheumatoidarthritis
AT caporaliroberto clinicalvalueofautoantibodiesinrheumatoidarthritis